Once-weekly islatravir / lenacapavir combination pill maintains HIV viral suppression
Islatravir plus ulonivirine shows promise for weekly oral HIV treatment
Long-acting injectable treatment superior to daily pills for adolescents in African trial
The untapped potential of CD8 cells
New antiretrovirals in the pipeline could be part of twice-yearly HIV treatment
African paediatric studies at CROI: HIV remission in children, three bnAbs in babies, two years on injectables in teens
Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year
Resistance following failure of injectable cabotegravir/rilpivirine may limit future treatment options
Broadly neutralising antibodies plus immune modulator may delay HIV rebound
